The Compounding Cleanroom Question
A pharmacy in Orlando wants to begin compounding a sterile ophthalmic solution for a local ophthalmology group. The pharmacy currently compounds only nonsterile oral suspensions in a back room that also houses the coffee maker and a storage shelf of OTC products. The pharmacist-in-charge, Dr. Chen, proposes to designate the back room as a 'cleanroom,' install a horizontal laminar airflow hood purchased used from a closing pharmacy, and begin compounding next week for 40 patients. The pharmacy has no written procedures for sterility assurance, no environmental monitoring, and no designated garb. Dr. Chen argues that because the solution is 'just saline with a drug in it,' the risk is low.
1. What regulatory category does this proposed sterile compounding fall into, and what must Dr. Chen do before compounding begins?
Read the worked answer
Sterile compounding is governed by USP <797> (adopted by reference in Florida Board rules) as well as Florida's compounding rules. The proposed activity - a sterile ophthalmic solution prepared in advance for multiple patients - is not a simple, immediate-use preparation.
Before any sterile compounding, the pharmacy must:
- Classify the preparation. Determine whether it is a low-risk, medium-risk, or high-risk preparation under USP <797>. A preserved or unpreserved ophthalmic solution prepared in batches for 40 patients is at least a medium-risk preparation (multiple components, batch preparation, longer beyond-use dating).
- Provide the physical environment. A proper cleanroom with an ISO Class 7 buffer area and an ISO Class 8 ante area, or a segregated compounding area with appropriate engineering controls, plus a primary engineering control (a vertical or horizontal laminar airflow hood) that is certified and located in the buffer area. A used hood of unknown certification history cannot simply be installed; it must be certified by a qualified certifier before use and at least every 6 months thereafter.
- Adopt written procedures. Standard operating procedures for garbing, hand hygiene, cleaning and sanitizing, environmental monitoring (viable and nonviable particle testing), end-product testing, and deviation handling.
- Environmental monitoring. Surface sampling and air sampling at defined intervals, with documented results and corrective action thresholds.
- Personnel training and validation. Garbing and aseptic technique validation (e.g., media-fill or gloved-fingertip testing) before compounding and at defined intervals.
- Designate the space. The back room with a coffee maker and OTC storage is not acceptable; the compounding area must be separated from other operations and free of food, drink, and unrelated traffic.
'Just saline with a drug in it' is not a legal risk category - the route of administration (ophthalmic, sterile) controls, not the perceived simplicity of the formula.
2. Dr. Chen proceeds anyway and dispenses the solution to the ophthalmology group. What are the potential consequences, and what should the Board expect to see if it inspects?
Read the worked answer
Dispensing a sterile compounded product without meeting USP <797> standards exposes the pharmacy and Dr. Chen to:
- Board discipline for compounding in violation of Board rules, including reprimand, suspension, restriction, or revocation of the pharmacy permit and the pharmacist's license, plus fines and costs.
- Federal exposure if the pharmacy is acting as a manufacturer (compounding for a prescriber's office in a way that exceeds traditional compounding), which can trigger FDA enforcement.
- Civil liability if any patient suffers an infection or injury from a nonsterile product.
On inspection, the Board (or its inspector) would expect to find:
- A certified primary engineering control with a current certification report.
- A cleanroom or segregated compounding area meeting the required ISO classifications, with documentation of the last certification.
- Written SOPs, training records, garbing validation records, and environmental monitoring logs.
- Master formulation records and compounding records for each batch, including beyond-use dating rationale.
- A policy for adverse event reporting and recall if a batch is later found to be nonsterile.
If the pharmacy cannot produce these, the inspector will likely cite deficiencies and may order the pharmacy to cease sterile compounding pending correction.